 "Aurobindo Pharma gets US nod for bacterial infection drug")
The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Cefadroxil for oral suspension USP in the strengths of 250mg/5mL and 500mg/5mL, Aurobindo Pharma said in a statement.
The product is the generic equivalent of Warner Chilcott Company Inc's Duricef for oral suspension in the same strengths, it added.
Also Read
Cefadroxil oral suspension has been approved out of the company's cephalosporin formulations manufacturing facility in Hyderabad, Aurobindo Pharma said.
The company now has a total of 187 abbreviated new drug application (ANDA) approvals (160 final approvals including 4 from Aurolife Pharma LLC and 27 tentative approvals) from USFDA, it added.
Shares of Aurobindo Pharma were trading at Rs 189.40 per scrip on BSE, down 1.04 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%